About Frontier Medicines
Frontier Medicines is a company based in San Francisco (United States) founded in 2018 by Roberto Zoncu, Daniel Nomura, and Chris Varma. Frontier Medicines has raised $235.5 million across 3 funding rounds from investors including GLPG, RA Capital and Driehaus. The company has 115 employees as of December 31, 2023. Frontier Medicines offers products and services including The Frontier™ Platform, AutoTAC™ Platform, and Precision Pipeline. Frontier Medicines operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter San Francisco, United States
- Employees 115 as on 31 Dec, 2023
- Founders Roberto Zoncu, Daniel Nomura, Chris Varma
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Frontier Medicines Corporation
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$235.5 M (USD)
in 3 rounds
-
Latest Funding Round
$80 M (USD), Series C
Feb 22, 2024
-
Investors
GLPG
& 11 more
-
Employee Count
115
as on Dec 31, 2023
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Frontier Medicines
Frontier Medicines offers a comprehensive portfolio of products and services, including The Frontier™ Platform, AutoTAC™ Platform, and Precision Pipeline.
Proprietary system using chemoproteomics and machine learning for medicine development.
Technology for targeted degradation of disease-causing proteins.
Pipeline focused on precision-based medicines for specific patient groups.
People of Frontier Medicines
Unlock access to complete
Unlock access to complete
Funding Insights of Frontier Medicines
Frontier Medicines has successfully raised a total of $235.5M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $80 million completed in February 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Frontier Medicines
Frontier Medicines has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include GLPG, RA Capital and Driehaus.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare ecosystem is supported through investment and innovation by Deerfield.
|
Locked | Locked | Locked | |
|
Droia Ventures is focused on investing in drug development companies.
|
Locked | Locked | Locked | |
|
Venture capital firm focused on multiple sectors
|
Locked | Locked | Locked |
Investor details for Frontier Medicines
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Frontier Medicines
Investment portfolio details for Frontier Medicines
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Frontier Medicines
Detailed financials for Frontier Medicines
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Frontier Medicines Comparisons
Peer comparison for Frontier Medicines
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Frontier Medicines
Frontier Medicines operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
Detailed competitors of Frontier Medicines
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Frontier Medicines
Complete news archive for Frontier Medicines
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Frontier Medicines
Frontier Medicines was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Frontier Medicines is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Chris Varma is the current CEO of Frontier Medicines. They have also founded this company.
Frontier Medicines is a funded company, having raised a total of $235.5M across 3 funding rounds to date.
As of Dec 31, 2023, the latest employee count at Frontier Medicines is 115.
Developer of a bioinformatics platform for drug development and chemoproteomics. The proprietary chemoproteomics platform uses machine learning technology to analyze proteins to identify active binding sites as drug targets to treat diseases. The platform consists of a database of hotspots in proteins, a library of chemically diverse compounds, and a novel approach to protein degradation. It ofefrs a lead program FMC-376, which is a novel dual inhibitor of both active and inactive KRASG12 for non-small cell lung, colorectal, and pancreatic cancers.
Frontier Medicines's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Frontier Medicines offers The Frontier™ Platform, AutoTAC™ Platform, and Precision Pipeline.
Frontier Medicines has 12 investors. Key investors include GLPG, RA Capital, Driehaus, ArrowMark Partners, and Deerfield.